{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:55:13Z","timestamp":1784919313238,"version":"3.55.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.idc.2022.08.004","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T19:45:31Z","timestamp":1667245531000},"page":"791-823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics"],"prefix":"10.1016","volume":"36","author":[{"given":"Cornelius J.","family":"Clancy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Hong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2022.08.004_bib1","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Available at: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"10.1016\/j.idc.2022.08.004_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2022.08.004_bib3","author":"O'Neill"},{"key":"10.1016\/j.idc.2022.08.004_bib4","author":"World Health Organization"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib5","doi-asserted-by":"crossref","first-page":"ofz344","DOI":"10.1093\/ofid\/ofz344","article-title":"Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data","volume":"6","author":"Clancy","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib6","doi-asserted-by":"crossref","first-page":"e01733-19","DOI":"10.1128\/AAC.01733-19","article-title":"Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae","volume":"63","author":"Clancy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/cid\/ciaa061","article-title":"Pharmacoepidemiology of ceftazidime-avibactam use: a retrospective cohort anlaysis of 210\u00a0US hospitals","volume":"72","author":"Strich","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib8","doi-asserted-by":"crossref","first-page":"ofaa464","DOI":"10.1093\/ofid\/ofaa464","article-title":"Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020","volume":"7","author":"Clancy","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2022.08.004_bib9","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib10","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-lactamase producing Enterobacterales, Carbapenem-resistant Acinetobacter baumainnii, and Stenotrophomas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2022.08.004_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cmi.2022.01.030","article-title":"IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections","volume":"28","author":"Lawandi","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib13","doi-asserted-by":"crossref","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New Perspectives on Antimicrobial Agents: Cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib14","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In\u00a0Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib15","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"Antibacterial Resistance Leadership G. A Primer on AmpC beta-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl A","key":"10.1016\/j.idc.2022.08.004_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/22.Supplement_A.37","article-title":"Induction of beta-lactamases","volume":"22","author":"Eliopoulos","year":"1988","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1128\/AAC.37.2.153","article-title":"Molecular basis of beta-lactamase induction in bacteria","volume":"37","author":"Bennett","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/clinids\/21.5.1107","article-title":"The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms","volume":"21","author":"Jacobson","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.idc.2022.08.004_bib19","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1073\/pnas.82.14.4620","article-title":"Regulatory components in Citrobacter freundii ampC beta-lactamase induction","volume":"82","author":"Lindberg","year":"1985","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/jac\/dkh235","article-title":"Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology","volume":"53","author":"Underwood","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib21","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1128\/AAC.45.8.2287-2298.2001","article-title":"Novel class A beta-lactamase Sed-1 from Citrobacter sedlakii: genetic diversity of beta-lactamases within the Citrobacter genus","volume":"45","author":"Petrella","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/am.23.3.592-594.1972","article-title":"Characterization of indole-positive Proteus mirabilis","volume":"23","author":"Matsen","year":"1972","journal-title":"Appl Microbiol"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib23","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent beta-Lactam-beta-Lactamase Inhibitor Combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1021\/bi9015549","article-title":"Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2","volume":"49","author":"Endimiani","year":"2010","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.00826-13","article-title":"New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world","volume":"58","author":"Drawz","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between beta-lactamases and new beta-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijantimicag.2012.10.022","article-title":"Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?","volume":"41","author":"Hilty","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/cid\/cit395","article-title":"The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae","volume":"57","author":"Tamma","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1128\/AAC.01083-07","article-title":"Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use","volume":"52","author":"Choi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","article-title":"Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy","volume":"115","author":"Chow","year":"1991","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib31","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.45.9.2628-2630.2001","article-title":"Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp","volume":"45","author":"Kaye","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib32","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jac\/dky084","article-title":"Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC beta-lactamase","volume":"73","author":"Kohlmann","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2022.08.004_bib33","first-page":"1282","article-title":"Three Yersinia enterocolitica AmpD Homologs Participate in the Multi-Step Regulation of Chromosomal Cephalosporinase, AmpC","volume":"7","author":"Liu","year":"2016","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1128\/AAC.36.5.1049","article-title":"Nucleotide sequence of the ampC-ampR region from the chromosome of Yersinia enterocolitica","volume":"36","author":"Seoane","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib35","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1128\/AAC.44.11.3220-3223.2000","article-title":"Heterogeneity of AmpC cephalosporinases of Hafnia alvei clinical isolates expressing inducible or constitutive ceftazidime resistance phenotypes","volume":"44","author":"Girlich","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2022.08.004_bib36","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The Use of Noncarbapenem beta-Lactams for the Treatment of Extended-Spectrum beta-Lactamase Infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2022.08.004_bib37","first-page":"31","article-title":"Antibacterial in\u00a0vitro activity of fourth generation cephalosporins","volume":"8","author":"Hancock","year":"1996","journal-title":"J\u00a0Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2022.08.004_bib38","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1469-0691.1999.tb00721.x","article-title":"In\u00a0vitro selective concentrations of cefepime and ceftazidime for AmpC beta-lactamase hyperproducer Enterobacter cloacae variants","volume":"5","author":"Negri","year":"1999","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkv346","article-title":"Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis","volume":"71","author":"Harris","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib40","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1128\/AAC.41.9.2013","article-title":"Penicillin-binding proteins and induction of AmpC beta-lactamase","volume":"41","author":"Sanders","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/AAC.34.1.156","article-title":"Diverse potential of beta-lactamase inhibitors to induce class I enzymes","volume":"34","author":"Weber","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2022.08.004_bib42","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.45.10.2831-2837.2001","article-title":"Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib43","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/cid\/ciu182","article-title":"Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia","volume":"58","author":"Siedner","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib44","doi-asserted-by":"crossref","first-page":"105860","DOI":"10.1016\/j.ijantimicag.2019.105860","article-title":"Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems","volume":"55","author":"Tan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib45","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1128\/AAC.48.3.1040-1042.2004","article-title":"Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate","volume":"48","author":"Barnaud","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib46","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1128\/JCM.43.9.4891-4894.2005","article-title":"Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia","volume":"43","author":"Song","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/516917","article-title":"Rapid emergence of resistance to cefepime during treatment","volume":"25","author":"Limaye","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib48","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1128\/AAC.40.12.2854","article-title":"Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes","volume":"40","author":"Charrel","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib49","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/AAC.40.5.1289","article-title":"Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins","volume":"40","author":"Fung-Tomc","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2022.08.004_bib50","unstructured":"Procter and Gamble Pharmaceuticals, Inc. MACROBID - nitrofurantoin monohydrate and nitrofurantoin, macrocrystalline capsule [package insert]. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020064s019lbl.pdf. Accessed October 24, 2022."},{"issue":"17","key":"10.1016\/j.idc.2022.08.004_bib52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2022.08.004_bib54","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjmed.2017.01.025","article-title":"A\u00a0Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis","volume":"130","author":"Fox","year":"2017","journal-title":"Am J Med"},{"issue":"14","key":"10.1016\/j.idc.2022.08.004_bib55","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib56","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/JCM.01687-08","article-title":"Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates","volume":"47","author":"Robberts","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.idc.2022.08.004_bib57","unstructured":"Clinical and Laboratory Standards Institute. M100: performance standards for antimicrobial susceptibility testing. 31st edition. Wayne (PA): Clinical and Laboratory Standards Institute; 2021."},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib58","doi-asserted-by":"crossref","first-page":"dlab019","DOI":"10.1093\/jacamr\/dlab019","article-title":"PRO: Testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress","volume":"3","author":"Tamma","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib59","doi-asserted-by":"crossref","first-page":"dlab020","DOI":"10.1093\/jacamr\/dlab020","article-title":"Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales","volume":"3","author":"Mathers","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib60","doi-asserted-by":"crossref","first-page":"ofz353","DOI":"10.1093\/ofid\/ofz353","article-title":"Molecular Epidemiology of Ceftriaxone Non-Susceptible Enterobacterales Isolates in an Academic Medical Center in the United States","volume":"6","author":"Tamma","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib62","doi-asserted-by":"crossref","first-page":"e00127-21","DOI":"10.1128\/JCM.00127-21","article-title":"Prevalence of bla CTX-M Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States","volume":"59","author":"Tamma","year":"2021","journal-title":"J\u00a0Clin Microbiol"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib63","doi-asserted-by":"crossref","first-page":"e00047-e19","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of beta-Lactamase-Producing Pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib64","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib65","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.01896-13","article-title":"Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib66","doi-asserted-by":"crossref","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum beta-lactamases: an update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"10","key":"10.1016\/j.idc.2022.08.004_bib67","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib68","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2022.08.004_bib69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13756-015-0055-6","article-title":"Comparable outcomes for beta-lactam\/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae","volume":"4","author":"Harris","year":"2015","journal-title":"Antimicrob Resist Infect Control"},{"issue":"7","key":"10.1016\/j.idc.2022.08.004_bib70","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jac\/dks088","article-title":"Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?","volume":"67","author":"Livermore","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2022.08.004_bib71","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2147\/IDR.S166790","article-title":"Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals","volume":"11","author":"Zhou","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib72","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QCO.0000000000000623","article-title":"Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia","volume":"33","author":"Paterson","year":"2020","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib73","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dky453","article-title":"OXA-1 beta-lactamase and non-susceptibility to penicillin\/beta-lactamase inhibitor combinations among ESBL-producing Escherichia coli","volume":"74","author":"Livermore","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib74","doi-asserted-by":"crossref","first-page":"ofw132","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib76","doi-asserted-by":"crossref","first-page":"e0153696","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib77","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib78","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2014.07.006","article-title":"Carbapenems and piperacillin\/tazobactam for the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis","volume":"80","author":"Tsai","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib79","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3906\/sag-1506-157","article-title":"Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam","volume":"46","author":"Dizbay","year":"2016","journal-title":"Turk J Med Sci"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib80","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib81","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijantimicag.2016.12.017","article-title":"Role of piperacillin\/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli","volume":"49","author":"Yoon","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib82","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1093\/cid\/ciz1205","article-title":"Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by ESBL-producing Organisms?","volume":"71","author":"Sharara","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s13104-019-4648-7","article-title":"Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam\/beta lactamase inhibitor therapy","volume":"12","author":"Nasir","year":"2019","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.idc.2022.08.004_bib84","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13756-019-0599-y","article-title":"Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016","volume":"8","author":"Xiao","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10096-017-3133-2","article-title":"Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study","volume":"37","author":"Ko","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2022.08.004_bib86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejim.2017.10.014","article-title":"Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward","volume":"48","author":"Meini","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib87","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.idc.2022.08.004_bib88","author":"Bitterman"},{"issue":"7","key":"10.1016\/j.idc.2022.08.004_bib89","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib90","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib91","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2003.11.007","article-title":"In\u00a0vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae","volume":"49","author":"Burgess","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib92","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2017.09.013","article-title":"Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing enterobacteriaceae","volume":"51","author":"Kim","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"11\u201312","key":"10.1016\/j.idc.2022.08.004_bib93","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.medmal.2014.09.004","article-title":"Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use","volume":"44","author":"Lepeule","year":"2014","journal-title":"Med Mal Infect"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib94","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.idc.2022.08.004_bib95","doi-asserted-by":"crossref","first-page":"ofz364","DOI":"10.1093\/ofid\/ofz364","article-title":"Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. beta-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis","volume":"6","author":"Punjabi","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2022.08.004_bib97","unstructured":"Centers for Disease Control and Prevention. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE): November 2015\u00a0Update - CRE Toolkit, 2015. Available at: https:\/\/www.cdc.gov\/hai\/pdfs\/cre\/cre-guidance-508.pdf."},{"key":"10.1016\/j.idc.2022.08.004_bib98","doi-asserted-by":"crossref","first-page":"e0110521","DOI":"10.1128\/AAC.01105-21","article-title":"Detection and Characterization of Targeted Carbapenem-Resistant Healthcare-Associated Threats: Findings from The Antibiotic Resistance Laboratory Network, 2017 to 2019","volume":"65","author":"Sabour","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib99","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2022.08.004_bib100","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/cid\/ciw398","article-title":"High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-beta-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center","volume":"63","author":"Aitken","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib101","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diagmicrobio.2018.10.004","article-title":"Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016","volume":"93","author":"Senchyna","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib102","doi-asserted-by":"crossref","first-page":"e01140-18","DOI":"10.1128\/JCM.01140-18","article-title":"Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates","volume":"56","author":"Tamma","year":"2018","journal-title":"J\u00a0Clin Microbiol"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib103","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dkz456","article-title":"In\u00a0vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17)","volume":"75","author":"Spiliopoulou","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib104","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/jac\/dkab306","article-title":"Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime\/avibactam, meropenem\/vaborbactam and comparators against these isolates","volume":"76","author":"Castanheira","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib105","doi-asserted-by":"crossref","first-page":"e01951-19","DOI":"10.1128\/AAC.01951-19","article-title":"Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018","volume":"64","author":"Castanheira","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib106","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","article-title":"In\u00a0vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/vaborbactam surveillance programme","volume":"52","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib107","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jpids\/piz002","article-title":"Defining the Role of Novel beta-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms","volume":"8","author":"Tamma","year":"2019","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib108","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib109","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2022.08.004_bib110","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib111","doi-asserted-by":"crossref","first-page":"e01426-19","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the Optimal Treatment for Metallo- and Serine-beta-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib112","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/jac\/dkz495","article-title":"Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime\/avibactam","volume":"75","author":"Sieswerda","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib113","doi-asserted-by":"crossref","first-page":"105842","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib114","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-beta-lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib115","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","article-title":"Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model","volume":"75","author":"Lodise","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib116","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","volume":"53","author":"De la Calle","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2022.08.004_bib117","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dkt142","article-title":"Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies","volume":"68","author":"Eckmann","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"38","key":"10.1016\/j.idc.2022.08.004_bib118","doi-asserted-by":"crossref","first-page":"e12467","DOI":"10.1097\/MD.0000000000012467","article-title":"Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib119","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib121","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib122","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib123","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2022.08.004_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2021.05.079","article-title":"Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia","volume":"109","author":"Hakeam","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.idc.2022.08.004_bib125","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Caston","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib126","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s12879-019-4409-1","article-title":"Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae","volume":"19","author":"Alraddadi","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib128","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib129","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib130","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2022.08.004_bib131","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/cid\/ciaa355","article-title":"Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib132","doi-asserted-by":"crossref","first-page":"e02497-17","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2022.08.004_bib133","doi-asserted-by":"crossref","first-page":"ofab371","DOI":"10.1093\/ofid\/ofab371","article-title":"Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa","volume":"8","author":"Alosaimy","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib134","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173\u00a0US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib135","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib136","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib137","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/138161213804070311","article-title":"Mechanisms of beta-lactam resistance among Pseudomonas aeruginosa","volume":"19","author":"Wolter","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib138","doi-asserted-by":"crossref","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In\u00a0Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2022.08.004_bib139","doi-asserted-by":"crossref","first-page":"e02569-17","DOI":"10.1128\/AAC.02569-17","article-title":"In\u00a0Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib140","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the In\u00a0Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib141","doi-asserted-by":"crossref","first-page":"e01955-19","DOI":"10.1128\/AAC.01955-19","article-title":"Activity of Cefiderocol and Comparators against Isolates from Cancer Patients","volume":"64","author":"Rolston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib142","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib143","doi-asserted-by":"crossref","first-page":"115012","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"In\u00a0Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib144","doi-asserted-by":"crossref","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","article-title":"In\u00a0Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib145","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In\u00a0Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib146","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib147","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib148","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib149","doi-asserted-by":"crossref","first-page":"FSO395","DOI":"10.2144\/fsoa-2018-0127","article-title":"Accurate identification of clinically important Acinetobacter spp.: an update","volume":"5","author":"Vijayakumar","year":"2019","journal-title":"Future Sci OA"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2022.08.004_bib150","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/504477","article-title":"Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa","volume":"43","author":"Bonomo","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib151","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib152","doi-asserted-by":"crossref","first-page":"e01576-17","DOI":"10.1128\/AAC.01576-17","article-title":"Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel beta-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii","volume":"62","author":"McLeod","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib153","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/jac\/dkt275","article-title":"TEM-1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii","volume":"68","author":"Krizova","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2022.08.004_bib154","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"Liu","year":"2021","journal-title":"J\u00a0Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib156","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3855\/jidc.6195","article-title":"Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia","volume":"9","author":"Yilmaz","year":"2015","journal-title":"J\u00a0Infect Dev Ctries"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib157","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib158","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib159","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib160","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.idc.2022.08.004_bib161","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jgar.2018.11.016","article-title":"Colistin monotherapy versus colistin\/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial","volume":"17","author":"Park","year":"2019","journal-title":"J\u00a0Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib162","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib163","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: an emerging global opportunistic pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib164","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/23744235.2018.1531145","article-title":"Stenotrophomonas maltophilia - a low-grade pathogen with numerous virulence factors","volume":"51","author":"Trifonova","year":"2019","journal-title":"Infect Dis (Lond)"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib165","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/AAC.00795-06","article-title":"Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia","volume":"51","author":"Okazaki","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib166","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jac\/dkp476","article-title":"Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia","volume":"65","author":"Gordon","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2022.08.004_bib167","doi-asserted-by":"crossref","first-page":"e02631-20","DOI":"10.1128\/AAC.02631-20","article-title":"Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia","volume":"65","author":"Khan","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2022.08.004_bib168","doi-asserted-by":"crossref","first-page":"e0065421","DOI":"10.1128\/JCM.00654-21","article-title":"Evaluation of the Vitek 2, Phoenix and Microscan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia","volume":"59","author":"Khan","year":"2021","journal-title":"J\u00a0Clin Microbiol"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib169","doi-asserted-by":"crossref","first-page":"e0152132","DOI":"10.1371\/journal.pone.0152132","article-title":"Evaluation of Trimethoprim\/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In\u00a0Vitro Time-Kill Experiments","volume":"11","author":"Wei","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2022.08.004_bib170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1476-0711-5-23","article-title":"Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem","volume":"5","author":"Al-Jasser","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib171","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/AAC.01682-13","article-title":"Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?","volume":"58","author":"Cho","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib172","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3349\/ymj.2014.55.4.987","article-title":"Clinical factors associated with acquisition of resistance to levofloxacin in Stenotrophomonas maltophilia","volume":"55","author":"Baek","year":"2014","journal-title":"Yonsei Med J"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib173","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3109\/23744235.2015.1064542","article-title":"A\u00a0Monte Carlo pharmacokinetic\/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia","volume":"47","author":"Wei","year":"2015","journal-title":"Infect Dis (Lond)"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib174","doi-asserted-by":"crossref","first-page":"e0156690","DOI":"10.1371\/journal.pone.0156690","article-title":"Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies","volume":"11","author":"Grillon","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib175","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/AAC.48.3.946-953.2004","article-title":"Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in\u00a0vitro pharmacokinetic-pharmacodynamic model","volume":"48","author":"Ba","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib176","doi-asserted-by":"crossref","first-page":"e00788-19","DOI":"10.1128\/AAC.00788-19","article-title":"Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections","volume":"63","author":"Nys","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib177","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/45.1.115","article-title":"Levofloxacin in\u00a0vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates","volume":"45","author":"Bonfiglio","year":"2000","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib178","doi-asserted-by":"crossref","first-page":"e01603-19","DOI":"10.1128\/JCM.01603-19","article-title":"Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and\/or Trimethoprim-Sulfamethoxazole","volume":"58","author":"Biagi","year":"2020","journal-title":"J\u00a0Clin Microbiol"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib179","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1473-3099(09)70083-0","article-title":"Stenotrophomonas maltophilia: an emerging opportunist human pathogen","volume":"9","author":"Looney","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib180","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.01774-09","article-title":"Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections","volume":"54","author":"Farrell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib181","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1128\/AAC.46.12.3997-3999.2002","article-title":"In\u00a0vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole","volume":"46","author":"Giamarellos-Bourboulis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib182","doi-asserted-by":"crossref","first-page":"e00559-20","DOI":"10.1128\/AAC.00559-20","article-title":"Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib183","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","volume":"74","author":"Hsueh","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"Suppl 7","key":"10.1016\/j.idc.2022.08.004_bib184","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In\u00a0Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2022.08.004_bib185","doi-asserted-by":"crossref","first-page":"e01558-19","DOI":"10.1128\/AAC.01558-19","article-title":"Comparative In\u00a0Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model","volume":"63","author":"Chen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib186","doi-asserted-by":"crossref","first-page":"e00297-20","DOI":"10.1128\/AAC.00297-20","article-title":"Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2022.08.004_bib187","doi-asserted-by":"crossref","first-page":"e00777-17","DOI":"10.1128\/AAC.00777-17","article-title":"Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam","volume":"61","author":"Mojica","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2022.08.004_bib188","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/jac\/dkv456","article-title":"Monotherapy with minocycline or trimethoprim\/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections","volume":"71","author":"Hand","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2022.08.004_bib189","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12866-021-02108-2","article-title":"Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in\u00a0vitro","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Microbiol"},{"issue":"11","key":"10.1016\/j.idc.2022.08.004_bib190","doi-asserted-by":"crossref","first-page":"e01433-20","DOI":"10.1128\/AAC.01433-20","article-title":"Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide","volume":"64","author":"Sader","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2022.08.004_bib191","doi-asserted-by":"crossref","first-page":"e00010-19","DOI":"10.1128\/AAC.00010-19","article-title":"Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-beta-Lactamase-Producing Gram-Negative Bacteria","volume":"63","author":"Emeraud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2022.08.004_bib192","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1128\/AAC.00264-16","article-title":"Successful Treatment of Bloodstream Infection Due to Metallo-beta-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient","volume":"60","author":"Mojica","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2022.08.004_bib193","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/clinids\/22.3.508","article-title":"Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes","volume":"22","author":"Muder","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2022.08.004_bib194","doi-asserted-by":"crossref","first-page":"ofab644","DOI":"10.1093\/ofid\/ofab644","article-title":"Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154\u00a0US Hospitals","volume":"9","author":"Sarzynski","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2022.08.004_bib195","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1093\/jac\/dkw327","article-title":"Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections","volume":"71","author":"Jacobson","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2022.08.004_bib196","doi-asserted-by":"crossref","first-page":"e0156690","DOI":"10.1371\/journal.pone.0156690","article-title":"Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies","volume":"11","author":"Grillon","year":"2016","journal-title":"PLoS One"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552022000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552022000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:30:42Z","timestamp":1760196642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552022000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":194,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0891552022000721"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2022.08.004","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2022.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}